The effects of high dose vitamin D supplementation as a nutritional intervention strategy on biochemical and inflammatory factors in adults with COVID-19: Study protocol for a randomized controlled trialCOVID-19 성인의 생화학적 및 염증 인자에 대한 영양 중재 전략으로서 고용량 비타민 D 보충제의 효과: 무작위 대조 시험을 위한 연구 프로토콜Article Published on 2022-09-012022-09-11 Journal: Nutrition and health [Category] 바이오마커, 임상, [키워드] All participant All participants Analysis baseline biochemical blood count both groups CBC changes in chest CT scan classification clinical outcomes complete blood count conducted confounders control group covariance COVID-19 Descriptive statistics diagnosis of COVID-19 double-blind duration of hospitalization Effect erythrocyte sedimentation erythrocyte sedimentation rate ESR Evidence followed by gel heart High dose hospitalized COVID-19 patients hs-CRP Imam in both groups Inflammation Inflammatory factor Inflammatory marker inflammatory markers intervention group Iran Laboratory life liver Mashhad mortality rate New York nutritional intervention parameter participant Patient performed Placebo protocol Quality of life randomization Randomized Randomized controlled trial receive recorded renal Reza risk factor RT-PCR sedimentation rate serum serum vitamin D shown study period Trial undergo Vitamin D Vitamin D supplementation with COVID-19 [DOI] 10.1177/02601060221082384 PMC 바로가기 [Article Type] Article
Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults뉴질랜드 성인에서 BNT162b2 COVID-19 백신의 면역원성Article Published on 2022-08-122022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] age All participant All participants analysed anti-S IgG Antibody Response baseline Beta BMI BNT162b2 BNT162b2 mRNA vaccine BNT162b2 vaccine Cellular immune response cellular immune responses co-morbidities Cohort COVID-19 COVID-19 disease COVID-19 vaccine declined Delta diabete diabetes diabetics disease dose enrichment Ethnic groups female Gender General population IgG immune response immune responses immunoassay immunogenicity in vitro International Lower Māori median age Microparticle morbidities morbidity naïve neutralise neutralising antibody neutralising response neutralising responses neutralizing capacity New obesity of BNT162b2 Older Older adults omicron other variant other variants Pacific Islander Population prospective cohort study pulmonary disease Quantitative recipient representation response risk robust SARS-CoV-2 vaccine second dose second vaccination serious COVID-19 seroconverted serum sample serum samples strain the vaccine Vaccine variant Viral viral neutralisation Wuhan [DOI] 10.1016/j.vaccine.2022.07.009 PMC 바로가기 [Article Type] Article
Atorvastatin for reduction of 28-day mortality in hospitalized COVID-19 patients: study protocol for a randomized, double-blinded, placebo-controlled, clinical trial입원한 COVID-19 환자의 28일 사망률 감소를 위한 아토르바스타틴: 무작위, 이중 맹검, 위약 대조, 임상 시험을 위한 연구 프로토콜Article Published on 2022-08-082022-09-11 Journal: Trials [Category] SARS, 임상, [키워드] 28-day mortality 95% confidence interval Acute kidney injury added adjusted odds ratio All participants all-cause mortality anti-inflammatory drug approval assigned atorvastatin being clinical Clinical improvement clinical trial clinician Consequences Consistency coronavirus COVID-19 COVID-19 patient Delta disease double-blinded drug events healthcare worker Hmg coa hospital hospitalized COVID-19 hospitalized patients In-hospital in-hospital mortality Informed consent institutional review board intensive care isolation hospital logistic regression model mass vaccination mechanical ventilation Mortality neurological once daily P-value pandemic pandemic era participant Patient performed Placebo placebo-controlled Primary outcome protocol Psychological Randomized randomized clinical trial Randomized controlled trial receive recruited reduce mortality reduced reduction Registered registry Research SARS-CoV-2 Sepsis severity severity of COVID-19 standard treatment statins Study protocol supported Tablet the patient university vaccination [DOI] 10.1186/s13063-022-06619-9 PMC 바로가기 [Article Type] Article
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialChAdOx1 nCoV-19 또는 BNT162b2 2회 접종 및 BNT162b2(COV-BOOST) 3차 접종 후 4차 접종으로 제공된 BNT162b2 및 mRNA-1273 COVID-19 백신의 안전성, 면역원성 및 반응성: 다기관, 맹검, 단계 2, 무작위 시험Clinical Trial Published on 2022-08-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 1:1 95% CI adverse event All participants analysed anti-spike protein IgG assigned blinded block size BNT162b2 boost booster Booster vaccine cellular Cellular and humoral immunity Cellular immune response ChAdOx1 nCoV-19 computer-generated Concentration Controlled trial country COV-BOOST COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Effectiveness ELISA ELISPOT Endpoint enrolled fatigue female Fold change Fold changes force geometric geometric mean groups Humoral immunity immunogenicity Intramuscular injection IQR ISRCTN Laboratory Local male median age median interval Moderna modified intention-to-treat mRNA mRNA-1273 mRNA-1273 booster mRNA-1273 COVID-19 vaccine multicentre of BNT162b2 outcome participant peak per-protocol population Pfizer-BioNTech Phase 2 random randomisation list randomised controlled trial Randomised trial Randomly reactogenicity receive Registered reported representing response Safety SARS-CoV-2 screened Serious Adverse Event seronegative participant seronegative participants serostatus Seven significant increase statistician T-cell Response T-cell responses Task Force the vaccine the vaccines titre treatment allocation Trial upper arm Vaccine variant were assessed wild-type [DOI] 10.1016/S1473-3099(22)00271-7 PMC 바로가기 [Article Type] Clinical Trial
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trialCOVID-19 회복기 참가자에 대한 FINLAY-FR-1A 백신의 안전성 및 면역원성: 공개 라벨 2a상 및 이중 맹검, 무작위 배정, 위약 대조, 2b상, 심리스, 임상 시험Clinical Trial Published on 2022-08-012022-09-11 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] 95% CI adverse event All participants Alpha anti-RBD antibody assigned Asymptomatic Beta clinical clinical trial clinical trials Complete control group control groups convalescent convalescent individual convalescent individuals COVID-19 criteria Cuba defined delta variant Delta variants dimeric double-blind education elicited ELISA Endpoint enrolled Environment evaluate evaluated experimental group first stage geometric mean geometric mean titre geometric mean titres greater hematology ICTRP IgG antibodies immune response immunogenicity immunology increase in injected injection injection site Intervention intervention group Mild minor Moderate COVID-19 natural immunity Negative PCR neutralisation test neutralising antibody Occurrence Open-label Pain participant Participants PCR test per-protocol population Phase 1 Phase 2 Placebo placebo group placebo-controlled prevaccination Primary outcome Primary outcomes Public randomised Randomly Receptor binding domain recruited Registered registry reported Safety safety analysis safety population safety profile SARS-CoV-2 Science seamless secondary Secondary endpoints Serious Adverse Event Serious Adverse Events seroconversion rate sexual single dose stages study population technology the placebo group titre Trial two groups vaccination Vaccine vaccine immunogenicity Virus neutralisation Volunteer was done WHO-ICTRP [DOI] 10.1016/S2213-2600(22)00100-X PMC 바로가기 [Article Type] Clinical Trial
Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccineBNT162b2 mRNA 백신 2회 접종 후 6개월 동안 일본 의료 종사자의 항체 역가 및 세포 면역의 역학Article Published on 2022-07-302022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 진단, 치료법, [키워드] All participant All participants Analysis antibody Antibody titer Antibody titers Asymptomatic BNT162b2 BNT162b2 mRNA BNT162b2 vaccine Breakthrough infection breakthrough infections Cellular immune response cellular immune responses cellular immunity clinical trial collected conducted COVID-19 determinant determinants determine dose Dynamics elevated follow-up period healthcare healthcare worker Healthcare workers humoral IgG immune response immune responses incidence Japanese knowledge medical condition Medical conditions mRNA vaccine mRNA vaccines Nucleocapsid proteins of BNT162b2 participant Pfizer Pfizer-BioNTech positive prospective cohort study receiving SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine seroconverted serum sample serum samples study period T-cell immune response T-cell immune responses timepoint vaccination Vaccine waned were measured within 6 months [DOI] 10.1016/j.vaccine.2022.06.016 PMC 바로가기 [Article Type] Article
Are Pain Polymorphisms Associated with the Risk and Phenotype of Post-COVID Pain in Previously Hospitalized COVID-19 Survivors?이전에 입원한 COVID-19 생존자의 통증 다형성이 COVID-19 이후 통증의 위험 및 표현형과 관련이 있습니까?Article Published on 2022-07-262022-09-11 Journal: Genes [Category] 변종, [키워드] All participants Anxiety association BDNF carried clinical feature Clinical features cognitive collected COMT COVID-19 de novo depressive distribution distributions Features female Gender Genotype Hospitalization hospitalized COVID-19 HTR1B involved kinesiophobia long-COVID Musculoskeletal neuropathic neuropathic pain no differences no effect not significantly different nucleotide OPRM1 Pain participant Participants participated phenotypic feature phenotypic features polymerase chain reaction polymerase chain reactions polymorphism Post-COVID Psychological risk rs4680 rs6265 selected sensitization single nucleotide Single nucleotide polymorphism sleep quality SNP SNPs survivor Survivors Symptom Symptoms variable variant were assessed [DOI] 10.3390/genes13081336 PMC 바로가기 [Article Type] Article
Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies: a longitudinal study based on patients with underlying diseases in Wuhan항-SARS-CoV-2 항체의 혈청유병률 및 역학: 우한의 기저 질환 환자를 기반으로 한 종단 연구Article Published on 2022-07-152022-09-11 Journal: Respiratory Research [Category] COVID19(2023년), MERS, SARS, 진단, 치료법, [키워드] 95% CI All participant All participants anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibody Antibody titer Assessing asymptomatic patient asymptomatic patients baseline Blood blood sample Blood samples change Community COVID-19 Diseases door effective family members feature Follow-up Government healthcare Households Humoral immunity IgA IgG IgG antibodies IgG antibody IgG titer IgG titers IgM immunoglobulins individual infected with SARS-CoV-2 list Local local government natural infection Neutralising Antibodies neutralising antibody Neutralizing antibody titer no significant difference nucleocapsid protein participant Participants Patient positive Prevention and control Protein provided questionnaire Randomly remained Research SARS-CoV-2 SARS-CoV-2 nucleocapsid selected serological Seroprevalence serum sample serum samples significantly Single natural infection symptomatic patient Symptomatic patients telephone tested titer total antibodies total antibody underlying disease underlying diseases venous venous blood was collected were assessed Wuhan [DOI] 10.1186/s12931-022-02096-5 PMC 바로가기 [Article Type] Article
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females남성과 여성에서 ChAdOx1 nCoV-19(AZD1222) 백신에 대한 반응에 대한 탐색적 분석Article Published on 2022-07-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 95% CI Academy adjusted age and sex All participant All participants anti-SARS-CoV-2 anti-Spike IgG AstraZeneca AZD1222 both sexes Brazil Cellular immune response ChAdOx1 ChAdOx1 nCoV-19 Chinese clinical Clinical research clinical trials Coalition Council COVID-19 COVID-19 vaccine COVID-19 vaccines defined dose doses Efficacy endpoints Engineering enrolled Evidence evidence of Exploratory analysis fatigue female females Fever first dose Follow-up foundation funding generate GMR greater headache humoral immune responses immunogenicity immunogenicity data immunological individual Innovation interaction term ISRCTN Linear model linear models log-transformed logistic regression models majority male males Medical Science NAAT nCoV network neutralisation assay NIHR no evidence of nucleic acid nucleic acid amplification nucleic acid amplification test Oxford participant Participants primary endpoint randomised randomised controlled trial reaction reactogenicity receive Registered Regression model reported SARS-COV-2 infection Science Sex Sex-differences shown single-blind South spike IgG Standard dose statistically significant difference Superior symptomatic SARS-CoV-2 infection systemic reaction Telle the primary endpoint titre trial participants vaccination Vaccine vaccine efficacy Vaccines Valley Volunteer [DOI] 10.1016/j.ebiom.2022.104128 PMC 바로가기 [Article Type] Article
Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine – A Prospective Observational StudyBNT162b2 COVID-19 백신의 3차 접종에 대한 세포 및 체액 면역 반응 - 전향적 관찰 연구Observational Study Published on 2022-07-012022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] addition administration All participant All participants anti-SARS-CoV-2 antibody binding binding antibody blood sample Blood samples BNT162b2 booster booster dose cellular Cellular immune response Combination COVID-19 detectable dose evaluate health-care humoral humoral and cellular immunity Humoral immunity immune response Immunity immunological infection rate infection rates interferon Interferon-gamma median Neutralizing antibodies neutralizing antibody observational study of BNT162b2 participant peptide peptides prime-boost regimen Prospective prospective observational study protocols provided quantitative assay questionnaire Questionnaires real-world data response SARS-CoV-2 second dose Seroprevalence significant increase significantly third dose vaccination Vaccine was measured were measured [DOI] 10.3389/fimmu.2022.896151 PMC 바로가기 [Article Type] Observational Study